{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:20:38Z","timestamp":1783056038366,"version":"3.54.6"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute (NIH\/NCI) Cancer Center Support Grant","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03239-x","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:12:39Z","timestamp":1772770359000},"page":"1091-1102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of direct oral anticoagulants and low molecular weight heparin for cancer-associated venous thromboembolism in patients with extremes in bodyweight"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-7309","authenticated-orcid":false,"given":"Katy M.","family":"Toale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2237-8317","authenticated-orcid":false,"given":"Claire A.","family":"Marten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-5762","authenticated-orcid":false,"given":"Ashley","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-9117","authenticated-orcid":false,"given":"Clark R.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-1202","authenticated-orcid":false,"given":"Fauzia","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-3929","authenticated-orcid":false,"given":"Cristhiam Mauricio","family":"Rojas Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"3239_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11739-015-1233-5","volume":"10","author":"M Verso","year":"2015","unstructured":"Verso M, Agnelli G, Prandoni P (2015) Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. Intern Emerg Med 10:651\u2013656. https:\/\/doi.org\/10.1007\/s11739-015-1233-5","journal-title":"Intern Emerg Med"},{"key":"3239_CR2","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1001\/archinte.160.22.3431","volume":"160","author":"JD Douketis","year":"2000","unstructured":"Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS (2000) Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 160:3431\u20133436. https:\/\/doi.org\/10.1001\/archinte.160.22.3431","journal-title":"Arch Intern Med"},{"key":"3239_CR3","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1200\/jco.2000.18.17.3078","volume":"18","author":"BA Hutten","year":"2000","unstructured":"Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, B\u00fcller HR (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18:3078\u20133083. https:\/\/doi.org\/10.1200\/jco.2000.18.17.3078","journal-title":"J Clin Oncol"},{"key":"3239_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1055\/s-0037-1614120","volume":"84","author":"G Palareti","year":"2000","unstructured":"Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D\u2019Angelo A, Pengo V, Moia M, Coccheri S (2000) A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 84:805\u2013810. https:\/\/doi.org\/10.1055\/s-0037-1614120","journal-title":"Thromb Haemost"},{"key":"3239_CR5","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484\u20133488. https:\/\/doi.org\/10.1182\/blood-2002-01-0108","journal-title":"Blood"},{"key":"3239_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146\u2013153. https:\/\/doi.org\/10.1056\/NEJMoa025313","journal-title":"N Engl J Med"},{"key":"3239_CR7","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/jco.23.00294","volume":"41","author":"NS Key","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A (2023) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 41:3063\u20133071. https:\/\/doi.org\/10.1200\/jco.23.00294","journal-title":"J Clin Oncol"},{"key":"3239_CR8","unstructured":"Streiff MB, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R et al (2025) Cancer-Associated Venous Thromboembolic Disease, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vte.pdf. Accessed 15 Oct 2025"},{"key":"3239_CR9","doi-asserted-by":"publisher","unstructured":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies (2004) Lancet 363:157\u2013163. https:\/\/doi.org\/10.1016\/S0140-6736(0)15268-3","DOI":"10.1016\/S0140-6736(0)15268-3"},{"key":"3239_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-11-8","volume":"11","author":"H Ten Cate","year":"2013","unstructured":"Ten Cate H (2013) New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J 11:8. https:\/\/doi.org\/10.1186\/1477-9560-11-8","journal-title":"Thromb J"},{"key":"3239_CR11","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jth.13323","volume":"14","author":"K Martin","year":"2016","unstructured":"Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2016) Use of the direct oral anticoagulants in obese patients: guidance from the ssc of the ISTH. J Thromb Haemost 14:1308\u20131313. https:\/\/doi.org\/10.1111\/jth.13323","journal-title":"J Thromb Haemost"},{"key":"3239_CR12","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/jth.15358","volume":"19","author":"KA Martin","year":"2021","unstructured":"Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2021) Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH ssc subcommittee on control of anticoagulation. J Thromb Haemost 19:1874\u20131882. https:\/\/doi.org\/10.1111\/jth.15358","journal-title":"J Thromb Haemost"},{"key":"3239_CR13","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119\u20132126. https:\/\/doi.org\/10.1111\/jth.13140","journal-title":"J Thromb Haemost"},{"key":"3239_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"3239_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane 2nd","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 18:411\u2013421. https:\/\/doi.org\/10.1111\/jth.14662","journal-title":"J Thromb Haemost"},{"key":"3239_CR16","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382:1599\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1915103","journal-title":"N Engl J Med"},{"key":"3239_CR17","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/jco.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M (2018) Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol 36:2017\u20132023. https:\/\/doi.org\/10.1200\/jco.2018.78.8034","journal-title":"J Clin Oncol"},{"key":"3239_CR18","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1345\/aph.1L194","volume":"43","author":"EA Nutescu","year":"2009","unstructured":"Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 43:1064\u20131083. https:\/\/doi.org\/10.1345\/aph.1L194","journal-title":"Ann Pharmacother"},{"key":"3239_CR19","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1177\/1060028018768449","volume":"52","author":"J Sebaaly","year":"2018","unstructured":"Sebaaly J, Covert K (2018) Enoxaparin dosing at extremes of weight: literature review and dosing recommendations. Ann Pharmacother 52:898\u2013909. https:\/\/doi.org\/10.1177\/1060028018768449","journal-title":"Ann Pharmacother"},{"key":"3239_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1055\/s-0040-1718405","volume":"46","author":"A Abildgaard","year":"2020","unstructured":"Abildgaard A, Madsen SA, Hvas AM (2020) Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin Thromb Hemost 46:932\u2013969. https:\/\/doi.org\/10.1055\/s-0040-1718405","journal-title":"Semin Thromb Hemost"},{"key":"3239_CR21","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/ejh.13471","volume":"105","author":"WE Wysokinski","year":"2020","unstructured":"Wysokinski WE, Froehling DA, Houghton DE, McBane RD, Vlazny DT, Bott-Kitslaar DM, Kuczmik W, Sutkowska K, Bator K, Hodge DO, Peterson LG, Casanegra AI (2020) Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight. Eur J Haematol 105:484\u2013494. https:\/\/doi.org\/10.1111\/ejh.13471","journal-title":"Eur J Haematol"},{"key":"3239_CR22","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.3390\/jcm13133784","volume":"13","author":"P Karakasis","year":"2024","unstructured":"Karakasis P, Ktenopoulos N, Pamporis K, Sagris M, Soulaidopoulos S, Gerogianni M, Leontsinis I, Giannakoulas G, Tousoulis D, Fragakis N, Tsioufis K (2024) Efficacy and safety of direct oral anticoagulants versus warfarin in obese patients (BMI \u2265 30 kg\/m(2)) with atrial fibrillation or venous thromboembolism: an updated systematic review and meta-analysis. J Clin Med 13:3784. https:\/\/doi.org\/10.3390\/jcm13133784","journal-title":"J Clin Med"},{"key":"3239_CR23","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1055\/a-1588-9155","volume":"122","author":"TF Wang","year":"2022","unstructured":"Wang TF, Carrier M, Fournier K, Siegal DM, Le Gal G, Delluc A (2022) Oral anticoagulant use in patients with morbid obesity: a systematic review and meta-analysis. Thromb Haemost 122:830\u2013841. https:\/\/doi.org\/10.1055\/a-1588-9155","journal-title":"Thromb Haemost"},{"key":"3239_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-023-03067-4","volume":"23","author":"DY Park","year":"2023","unstructured":"Park DY, An S, Arif AW, Sana MK, Vij A (2023) Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. BMC Cardiovasc Disord 23:100. https:\/\/doi.org\/10.1186\/s12872-023-03067-4","journal-title":"BMC Cardiovasc Disord"},{"key":"3239_CR25","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1177\/1060028020923584","volume":"54","author":"J Sebaaly","year":"2020","unstructured":"Sebaaly J, Kelley D (2020) Direct oral anticoagulants in obesity: an updated literature review. Ann Pharmacother 54:1144\u20131158. https:\/\/doi.org\/10.1177\/1060028020923584","journal-title":"Ann Pharmacother"},{"key":"3239_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.thromres.2023.04.015","volume":"226","author":"N Potere","year":"2023","unstructured":"Potere N, Di Nisio M, Porreca E, Wang TF, Tagalakis V, Shivakumar S, Delluc A, Mallick R, Wells PS, Carrier M (2023) Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: insights from the AVERT trial. Thromb Res 226:82\u201385. https:\/\/doi.org\/10.1016\/j.thromres.2023.04.015","journal-title":"Thromb Res"},{"key":"3239_CR27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/0091270006296058","volume":"47","author":"D Kubitza","year":"2007","unstructured":"Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59\u20137939) in healthy subjects. J Clin Pharmacol 47:218\u2013226. https:\/\/doi.org\/10.1177\/0091270006296058","journal-title":"J Clin Pharmacol"},{"key":"3239_CR28","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/bcp.12114","volume":"76","author":"VV Upreti","year":"2013","unstructured":"Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, LaCreta FP, Frost CE (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 76:908\u2013916. https:\/\/doi.org\/10.1111\/bcp.12114","journal-title":"Br J Clin Pharmacol"},{"key":"3239_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.thromres.2016.09.010","volume":"147","author":"D Arachchillage","year":"2016","unstructured":"Arachchillage D, Reynolds R, Devey T, Maclean R, Kitchen S, van Veen JJ (2016) Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience. Thromb Res 147:32\u201335. https:\/\/doi.org\/10.1016\/j.thromres.2016.09.010","journal-title":"Thromb Res"},{"key":"3239_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/07853890.2014.982064","volume":"47","author":"MN Di Minno","year":"2015","unstructured":"Di Minno MN, Lupoli R, Di Minno A, Ambrosino P, Scalera A, Dentali F (2015) Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials. Ann Med 47:61\u201368. https:\/\/doi.org\/10.3109\/07853890.2014.982064","journal-title":"Ann Med"},{"key":"3239_CR31","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/jth.13701","volume":"15","author":"K Boonyawat","year":"2017","unstructured":"Boonyawat K, Caron F, Li A, Chai-Adisaksopha C, Lim W, Iorio A, Lopes RD, Garcia D, Crowther MA (2017) Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost 15:1322\u20131333. https:\/\/doi.org\/10.1111\/jth.13701","journal-title":"J Thromb Haemost"},{"key":"3239_CR32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/ajhp\/zxaa059","volume":"77","author":"K Covert","year":"2020","unstructured":"Covert K, Branam DL (2020) Direct-acting oral anticoagulant use at extremes of body weight: literature review and recommendations. Am J Health-Syst Pharm 77:865\u2013876. https:\/\/doi.org\/10.1093\/ajhp\/zxaa059","journal-title":"Am J Health-Syst Pharm"},{"key":"3239_CR33","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1302507","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03239-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03239-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03239-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:00:28Z","timestamp":1783054828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03239-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["3239"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03239-x","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cristhiam Mauricio Rojas Hernandez received funding from ANTHOS therapeutics (clinical research funding for Abelacimab versus apixaban for cancer associated thrombosis). The other authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of the University of Texas MD Anderson Cancer Center approved this study and the need for informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}